Mealey's (June 16, 2022, 1:33 PM EDT) -- PHILADELPHIA — A Third Circuit U.S. Court of Appeals panel on June 14 agreed with a federal district court that shareholders in a securities class action failed to sufficiently plead that a pharmaceutical company and several of its senior executives violated federal securities law by misrepresenting topline data from a Phase 3 clinical trial for the drug maker’s heart disease drug because the shareholders failed to plead any actionable misstatement or omission....